论文部分内容阅读
目的研究Ⅱb/Ⅲa受体拮抗剂盐酸替罗非班对急诊经皮冠状动脉介入治疗(PCI)的急性冠脉综合征(ACS)患者的血流灌注影响。方法选择2005年12月至2008年2月中国医科大学附属第四医院急诊治疗的147例ACS患者为研究对象。治疗组(72例)行急诊PCI治疗同时静脉推注盐酸替罗非班,对照组(75例)直接行PCI治疗。应用心肌灌注分级(TMP)和心电图ST段变化(sumSTR)法评价急诊PCI时心肌组织的再灌注情况。结果盐酸替罗非班可使PCI前梗死相关血管TIMI血流分级提高,治疗组有68例(94.44%)心肌灌注良好,4例(5.56%)心肌灌注不良;对照组中64例(85.33%)心肌灌注良好,11例(14.67%)心肌灌注不良,两组间比较差异有统计学意义(P<0.05)。sumSTR评价结果:治疗组有68例心肌灌注良好(94.44%),4例心肌灌注不良(5.56%);而对照组中有62例心肌灌注良好(82.67%),13例心肌灌注不良(17.33%),两组间比较差异有统计学意义(P<0.05)。结论盐酸替罗非班可改善急性冠脉综合征患者相关血管的血流灌注。
Objective To investigate the effects of Ⅱb / Ⅲa receptor antagonist tirofiban on perfusion of acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). Methods A total of 147 patients with ACS undergoing emergency treatment at the Fourth Affiliated Hospital of China Medical University from December 2005 to February 2008 were selected as the study subjects. The treatment group (n = 72) underwent emergency PCI while intravenous infusion of tirofiban hydrochloride, while the control group (n = 75) received PCI directly. Cardiac perfusion grading (TMP) and electrocardiographic ST-segment changes (sumSTR) were used to evaluate the myocardial reperfusion during emergency PCI. Results Tirofiban hydrochloride improved infarction-related vascular TIMI grade in PCI, 68 cases (94.44%) had myocardial perfusion in the treatment group and 4 cases (5.56%) had myocardial perfusion defect in the control group. 64 cases (85.33% ) Myocardial perfusion, 11 cases (14.67%) myocardial perfusion, the difference between the two groups was statistically significant (P <0.05). The results of sumSTR showed that there were 68 cases with myocardial perfusion (94.44%) and 4 cases with myocardial perfusion (5.56%) in the treatment group, 62 cases with myocardial perfusion (82.67%) and 13 cases with myocardial perfusion (17.33% ), The difference between the two groups was statistically significant (P <0.05). Conclusion Tirofiban Hydrochloride can improve the perfusion of related blood vessels in patients with acute coronary syndrome.